Bococizumab

	WikiDoc Resources for Bococizumab
Articles
Most recent articles on Bococizumab Most cited articles on Bococizumab Review articles on Bococizumab Articles on Bococizumab in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Bococizumab Images of Bococizumab Photos of Bococizumab Podcasts & MP3s on Bococizumab Videos on Bococizumab
Evidence Based Medicine
Cochrane Collaboration on Bococizumab Bandolier on Bococizumab TRIP on Bococizumab
Clinical Trials
Ongoing Trials on Bococizumab at Clinical Trials.gov Trial results on Bococizumab Clinical Trials on Bococizumab at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Bococizumab NICE Guidance on Bococizumab NHS PRODIGY Guidance FDA on Bococizumab CDC on Bococizumab
Books
Books on Bococizumab
News
Bococizumab in the news Be alerted to news on Bococizumab News trends on Bococizumab
Commentary
Blogs on Bococizumab
Definitions
Definitions of Bococizumab
Patient Resources / Community
Patient resources on Bococizumab Discussion groups on Bococizumab Patient Handouts on Bococizumab Directions to Hospitals Treating Bococizumab Risk calculators and risk factors for Bococizumab
Healthcare Provider Resources
Symptoms of Bococizumab Causes & Risk Factors for Bococizumab Diagnostic studies for Bococizumab Treatment of Bococizumab
Continuing Medical Education (CME)
CME Programs on Bococizumab
International
Bococizumab en Espanol Bococizumab en Francais
Business
Bococizumab in the Marketplace Patents on Bococizumab
Experimental / Informatics
List of terms related to Bococizumab

Pharmacologic interventions for PCSK9 *Adapted from Journal of the American College of Cardiology, 62(16): 1401-1408*^[1]

For a review of all PCSK9 inhibitors please click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Bococizumab (PF-04950615; RN316) is a humanized monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 and is an investigational agent for the reduction of LDL-C levels in patients with hypercholesterolemia.

Properties

Major Trials

Phase II Trials

Phase III Trials

References

↑ Urban, D.; Pöss, J.; Böhm, M.; Laufs, U. (2013). "Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis". J Am Coll Cardiol. 62 (16): 1401–8. doi:10.1016/j.jacc.2013.07.056. PMID 23973703. Unknown parameter |month= ignored (help)

Template:WikiDoc Sources

[Urban-2013-1] Urban, D.; Pöss, J.; Böhm, M.; Laufs, U. (2013). "Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis". J Am Coll Cardiol. 62 (16): 1401–8. doi:10.1016/j.jacc.2013.07.056. PMID 23973703. Unknown parameter |month= ignored (help)

[1]

v t e Lipopedia
Basic Science	Cholesterol • Triglyceride Lipoprotein metabolism and transport Lipoprotein: Chylomicron • Chylomicron remnant • HDL • IDL • LDL • Lipoprotein(a) • VLDL • Lipoprotein-X Apolipoprotein: APOA (1, 2, 4, 5) • APOB ( Apolipoprotein B-48, Apolipoprotein B-100) • APOC (1, 2, 3, 4) • APOD • APOE • APOH • APOJ • APOL • APOM • Apo(a) Lipoprotein receptor: LDL receptor • Soluble low density lipoprotein receptor-related protein (sLRP) • Apolipoprotein E Receptor 2 • Scavenger receptor • Scavenger receptor A • Scavenger receptor B • VLDL receptor Lipoprotein enzymes: Lipoprotein lipase • Lipoprotein-associated phospholipase A2 (Lp-PLA2) • Cholesterylester transfer protein ( Acetyl-CoA C-acyltransferase, Lecithin-cholesterol acyltransferase) • Microsomal triglyceride transfer protein • ABCA1 Genes: Low density lipoprotein receptor gene family • Microsomal triglyceride transfer protein • ABCA1
Lipoprotein Disorders	Lipoprotein disorders Primary lipoprotein disorders: Familial hyperchylomicronemia (Type I) • Familial hypercholesterolemia (Type IIA) • Familial combined hyperlipidemia (Type IIB) • Dysbetalipoproteinemia (Type III) • Primary hypertriglyceridemia (Type IV) • Mixed hyperlipoproteinemia (Type V) Secondary lipoprotein disorders
Abnormal Laboratory Lipid Profile	Low chylomicron • Low chylomicron remnant • Low HDL • Low IDL • Low LDL • Low lipoprotein(a) • Low VLDL High chylomicron • High chylomicron remnant • High HDL • High IDL • High LDL • High Lipoprotein(a) • High VLDL